Interpace Diagnostics Group (NASDAQ:IDXG) has been assigned a $4.00 price target by Maxim Group in a report released on Wednesday. The firm presently has a “buy” rating on the business services provider’s stock. Maxim Group’s price target indicates a potential upside of 179.72% from the stock’s current price.
Several other analysts also recently issued reports on the company. HC Wainwright set a $3.00 price objective on Interpace Diagnostics Group and gave the company a “buy” rating in a research report on Friday, August 10th. Dawson James began coverage on Interpace Diagnostics Group in a research report on Wednesday, October 17th. They issued a “buy” rating and a $4.00 price objective on the stock. Zacks Investment Research upgraded Interpace Diagnostics Group from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Wednesday, August 22nd. Finally, ValuEngine upgraded Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Interpace Diagnostics Group has an average rating of “Buy” and an average target price of $3.17.
Interpace Diagnostics Group stock traded up $0.04 during trading hours on Wednesday, hitting $1.43. The stock had a trading volume of 2,590 shares, compared to its average volume of 371,222. The firm has a market capitalization of $38.60 million, a price-to-earnings ratio of -1.77 and a beta of 2.26. Interpace Diagnostics Group has a 1-year low of $0.77 and a 1-year high of $1.78.
Several large investors have recently modified their holdings of the company. Perkins Capital Management Inc. purchased a new stake in shares of Interpace Diagnostics Group in the third quarter valued at $983,000. Essex Investment Management Co. LLC purchased a new stake in shares of Interpace Diagnostics Group in the third quarter valued at $465,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Interpace Diagnostics Group in the third quarter valued at $194,000. Institutional investors and hedge funds own 15.59% of the company’s stock.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.